Although hematopoietic stem cell transplantation remains curative for select IEIs, post-transplant malignancy risk persists. A deeper understanding of shared molecular pathways linking immunodeficiency and cancer is essential to refine early diagnosis, risk stratification, and targeted management in this vulnerable population.
Özbay et al. (Mon,) studied this question.